AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.006

-0.001-14.29%

Volume:1.28M

Turnover:9K

Market Cap:28.27M

PE:-0.34

High:0.007

Open:0.007

Low:0.006

Close:0.007

52wk High:0.040

52wk Low:0.006

Shares:4.71B

Float Shares:3.34B

Volume Ratio:0.24

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-174.71%

ROA:-44.61%

PB:1.14

PE(LYR):-0.34

Loading ...

Overview Company News Filings

Radiopharm Theranostics Ltd-Radoc New Class Options Range of Units and Top 20 Holders

THOMSON REUTERS

Radiopharm Theranostics Ltd-Share Purchase Plan Completed

THOMSON REUTERS

Radiopharm Says Interim Phase 2b Rad101 PET Trial Meets Primary Endpoint with 93% MRI Concordance

Press Release: Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of Rad101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Holds General Meeting; All Resolutions Carried by Poll

Radiopharm Reports Positive Phase 1 Imaging Data for Rad301 in Pancreatic Cancer Patients

Radiopharm Theranostics - Significant Tumor Uptake Observed in All Evaluable Pancreatic Cancer Patients

THOMSON REUTERS

Radiopharm Theranostics - Positive Safety and Favorable Biodistribution Observed in All Subjects Dosed with Rad301

THOMSON REUTERS

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of Rad301 in Patients with Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS

Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026

THOMSON REUTERS

Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln

THOMSON REUTERS

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors

THOMSON REUTERS

Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review

Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution

THOMSON REUTERS

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial

THOMSON REUTERS

Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors

THOMSON REUTERS

Radiopharm Teams up with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial

Radiopharm Theranostics - Rad101 Receives FDA Fast Track Designation for Brain Metastases Diagnosis

THOMSON REUTERS

Radiopharm Theranostics - Schedules End-of-Phase 2 FDA Meeting for Rad101 Phase 3 Trial on Oct 1, 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/RAD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.006,"timestamp":1790748720000,"preClose":0.007,"halted":0,"volume":1284520,"delay":0,"changeRate":-0.14285714285714285,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4710883000,"eps":-0.0179,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"09-30 16:12:00 AEST","open":0.007,"high":0.007,"low":0.006,"amount":8937,"amplitude":0.142857,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0179,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1790812800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.007,"openAndCloseTimeList":[[1790726400000,1790748000000]],"volumeRatio":0.2442987604993971,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.006,"auctionPrice":0.007,"auctionVolume":166667,"auctionTime":1790808296538,"referenceTime":1790764203089,"auction":1,"marketStatus":"盘前竞价","timestamp":1790808296538}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-44.61%","roe":"-174.71%","lyrEps":-0.0179,"volumeRatio":0.2442987604993971,"shares":4710883000,"dividePrice":0,"high":0.007,"amplitude":0.142857,"preClose":0.007,"low":0.006,"week52Low":0.006,"pbRate":"1.14","psRate":"2.09","week52High":0.04,"institutionHeld":0,"latestPrice":0.006,"eps":-0.0179,"divideRate":0,"volume":1284520,"delay":0,"ttmEps":-0.0179,"open":0.007,"prevYearClose":0.025,"prevWeekClose":0.008,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.007,"twentyDayClose":0.009,"sixtyDayClose":0.02,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668934062","title":"Radiopharm Theranostics Ltd-Radoc New Class Options Range of Units and Top 20 Holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2668934062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668934062?lang=en_us&edition=fundamental","pubTime":"2026-09-17 08:41","pubTimestamp":1789605709,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUE53N4TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668931040","title":"Radiopharm Theranostics Ltd-Share Purchase Plan Completed","url":"https://stock-news.laohu8.com/highlight/detail?id=2668931040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668931040?lang=en_us&edition=fundamental","pubTime":"2026-09-17 08:11","pubTimestamp":1789603913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUE2RCYWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667572665","title":"Radiopharm Says Interim Phase 2b Rad101 PET Trial Meets Primary Endpoint with 93% MRI Concordance","url":"https://stock-news.laohu8.com/highlight/detail?id=2667572665","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667572665?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:05","pubTimestamp":1789387544,"startTime":"0","endTime":"0","summary":"Radiopharm says interim Phase 2b RAD101 PET trial meets primary endpoint with 93% MRI concordanceRadiopharm Theranostics flagged positive interim Phase 2b imaging data for RAD101 in suspected recurren","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL54ZDHc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","BK4112","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK7067","NDAQ","BK4585","LU2095319765.USD","BK4588","IE00BN0W2W23.USD","LU0314104364.USD","RAD.AU","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667037663","title":"Press Release: Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of Rad101 at 2026 Society of Neuro-Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2667037663","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667037663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":"RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpointMeeting with FDA planned on October 1(st) to align on RAD101Phase 3 pivotal trial pro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRS","RADX","BK7067","BK4139","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666552177","title":"Radiopharm Theranostics Holds General Meeting; All Resolutions Carried by Poll","url":"https://stock-news.laohu8.com/highlight/detail?id=2666552177","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666552177?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:02","pubTimestamp":1789128139,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics holds general meeting; all resolutions carried by pollRadiopharm Theranostics held a general meeting on Friday.Shareholders ratified the prior issue of First Tranche Placement ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL9bVlB2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666551587","title":"Radiopharm Reports Positive Phase 1 Imaging Data for Rad301 in Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551587","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:04","pubTimestamp":1788951890,"startTime":"0","endTime":"0","summary":"Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer patientsRadiopharm Theranostics reported positive Phase 1 imaging results for RAD301 in healthy volunteers, patients wi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL79Nw0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","BK7067","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BQXX3D17.EUR","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","LU0314104364.USD","RAD.AU","IE00BQXX3C00.GBP","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666958797","title":"Radiopharm Theranostics - Significant Tumor Uptake Observed in All Evaluable Pancreatic Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2666958797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666958797?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587975","title":"Radiopharm Theranostics - Positive Safety and Favorable Biodistribution Observed in All Subjects Dosed with Rad301","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587975?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666090582","title":"Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of Rad301 in Patients with Pancreatic Ductal Adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2666090582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666090582?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA58SJGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051887","title":"Radiopharm Theranostics - no Dividends Paid or Declared for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051887?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051884","title":"Radiopharm Theranostics - Prelim Loss for the Year Attributable up 50.3% to A$55.15 Mln for Year Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051884?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662051881","title":"Radiopharm Theranostics - FY Prelim Revenue from Contracts with Customers A$2.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662051881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662051881?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:09","pubTimestamp":1787897342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nFWN44O1LG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718764","title":"Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of Betabart (Rv-01) in B7-H3 Expressing Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718764","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718764?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:00","pubTimestamp":1787742001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nTUA86WLSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286639","title":"Radiopharm Theranostics Advances 177Lu-Rad202 Phase 1 HEAT Trial to 180 mCi Dose Cohort After DSMC Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286639","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286639?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:03","pubTimestamp":1787223813,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics advances 177Lu-RAD202 Phase 1 HEAT trial to 180 mCi dose cohort after DSMC reviewRadiopharm Theranostics moved its Phase 1 HEAT trial of 177Lu-RAD202 into Cohort 4 following a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL8L5MBh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","IE00BQXX3D17.EUR","SG9999014021.USD","IE00BQXX3F31.USD","BK4585","RAD.AU","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","BK7067","LU2210149790.SGD","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4588","LU0314104364.USD","BCDF","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660728687","title":"Radiopharm Theranostics - Rad202 Study Shows Clinical Proof-of-Concept with Positive Safety and Biodistribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2660728687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660728687?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332286","title":"Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-Rad202 Phase 1 Heat Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332286?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286382","title":"Radiopharm Theranostics - Advances Rad202 Phase 1 Trial to 180Mci Dose in Her2-Positive Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286382?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:00","pubTimestamp":1787223601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABR8NCB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482805","title":"Radiopharm Teams up with Siemens Healthineers to Manufacture, Distribute Rad101 Doses for US Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482805","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482805?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:31","pubTimestamp":1786966297,"startTime":"0","endTime":"0","summary":"Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trialRadiopharm Theranostics entered a partnership with Siemens Healthineers to manufacture, distri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL3jXZZb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","RAD.AU","BK7067","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828634","title":"Radiopharm Theranostics - Rad101 Receives FDA Fast Track Designation for Brain Metastases Diagnosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828634?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:30","pubTimestamp":1786966200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA2CWZWY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660828624","title":"Radiopharm Theranostics - Schedules End-of-Phase 2 FDA Meeting for Rad101 Phase 3 Trial on Oct 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2660828624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660828624?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:30","pubTimestamp":1786966200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA2CWZWY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":71,"code":"91000000","status":"200"}]}}